Who is sponsoring NCT03398915?

NCT03398915 is sponsored by Marc Schröder.

What drugs are being tested in NCT03398915?

Interventions in NCT03398915: Transpedicular Instrumentation.

What condition does NCT03398915 study?

NCT03398915 studies Degenerative Disc Disease, Spondylolisthesis, Spinal Stenosis, Recurrent Disc Herniation, Spondylodiskitis, Spinal Tumor, Spinal Metastases.

Is NCT03398915 still recruiting?

NCT03398915 is currently active, enrolled. Last updated 31 March 2026.

Are results published for NCT03398915?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-03-31 · How we verify

NCT03398915: EUROSPIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The European Robotic Spinal Instrumentation (EUROSPIN) Study

Active, enrolled Results posted Last updated 31 March 2026

What this trial tests

trial testing Transpedicular Instrumentation in Degenerative Disc Disease in 932 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2019

Primary endpoint
30 January 2026

1 May 2026

Quick facts

Lead sponsor	Marc Schröder
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	932
Start date	1 January 2019
Primary completion	30 January 2026
Estimated completion	1 May 2026
Sites	12 locations across France, Italy, Netherlands, Austria, Germany, Switzerland, Spain

Drugs / interventions tested

Transpedicular Instrumentation

Conditions studied

Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
Spondylolisthesis — all drugs for Spondylolisthesis →
Spinal Stenosis — all drugs for Spinal Stenosis →
Recurrent Disc Herniation — all drugs for Recurrent Disc Herniation →

Sponsor

Marc Schröder

Who can join

18 and older, any sex, with Degenerative Disc Disease or Spondylolisthesis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Revision Surgery for a Malpositioned Pedicle Screw Primary · 12 months

We defined the primary endpoint as required revision surgery for a malpositioned or loosened pedicle screw within the first postoperative year.

Group	Value	95% CI
Robot Guided	4
Navigated	7
Freehand	4

Adverse events — posted to ClinicalTrials.gov

Time frame: 1 year. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Robot-Guided Transpedicular Instrumentation

Serious: 4/389 (1%)

Deaths: 1/389

Navigated Transpedicular Instrumentation

Serious: 7/198 (4%)

Deaths: 11/198

Freehand Transpedicular Instrumentation

Serious: 4/315 (1%)

Deaths: 8/315

Serious adverse events (1 terms)

Reaction	System	Robot-Guided Transpedicula…	Navigated Transpedicular I…	Freehand Transpedicular In…
Revision Surgery for Malposition/Loosening	Musculoskeletal and connective tissue disorders	—	—	—

Other adverse events (1 terms — click to expand)

Reaction	System	Robot-Guided Transpedicula…	Navigated Transpedicular I…	Freehand Transpedicular In…
Surgical Complications	Surgical and medical procedures	—	—	—

Most-reported serious reactions: Revision Surgery for Malposition/Loosening.

Data from ClinicalTrials.gov NCT03398915 adverse events section.

Sponsor's own description

In a multinational prospective study, preoperative, intraoperative, perioperative and follow-up data on patients receiving thoracolumbar pedicle screw placement for degenerative disease or infections or tumors will be collected. The three arms consist of robot-guided (RG), navigated (NV), or freehand (FH) screw insertion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The European Robotic Spinal Instrumentation (EUROSPIN) study: protocol for a multicentre prospective observational study of pedicle screw revision surgery after robot-guided, navigated and freehand thoracolumbar spinal fusion.
Staartjes VE, Molliqaj G, van Kampen PM, Eversdijk HAJ, et al · · 2019 · cited 14× · PMID 31501123 · DOI 10.1136/bmjopen-2019-030389

Verify or expand the search:

Other recruiting trials for Degenerative Disc Disease

Currently open trials in the same condition.

NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
NCT06704919 — Conduit Cages and Fibergraft BG Putty · recruiting
NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting

Other Marc Schröder trials

Trials by the same sponsor.

NCT03303300 — The Five-repetition Sit-to-stand Test for Lower Back Pain or Radiculopathy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03398915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marc Schröder
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03398915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing